Literature DB >> 9380667

The immunologist's grail: vaccines that generate cellular immunity.

M A Liu1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9380667      PMCID： PMC33772          DOI： 10.1073/pnas.94.20.10496

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  17 in total

1.  Toxin entry: how reversible is the secretory pathway?

Authors:  H R Pelham; L M Roberts; J M Lord
Journal:  Trends Cell Biol       Date:  1992-07       Impact factor: 20.808

Review 2.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

3.  Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.

Authors:  S Koenig; A J Conley; Y A Brewah; G M Jones; S Leath; L J Boots; V Davey; G Pantaleo; J F Demarest; C Carter
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

4.  Transloading of tumor antigen-derived peptides into antigen-presenting cells.

Authors:  M Buschle; W Schmidt; W Zauner; K Mechtler; B Trska; H Kirlappos; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.

Authors:  M F Saron; C Fayolle; P Sebo; D Ladant; A Ullmann; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

Authors:  V Bronte; M W Carroll; T J Goletz; M Wang; W W Overwijk; F Marincola; S A Rosenberg; B Moss; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Barnase toxin: a new chimeric toxin composed of pseudomonas exotoxin A and barnase.

Authors:  T I Prior; D J FitzGerald; I Pastan
Journal:  Cell       Date:  1991-03-08       Impact factor: 66.850

8.  Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin.

Authors:  J J Donnelly; J B Ulmer; L A Hawe; A Friedman; X P Shi; K R Leander; J W Shiver; A I Oliff; D Martinez; D Montgomery
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 12.779

9.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

Authors:  A Townsend; J Bastin; K Gould; G Brownlee; M Andrew; B Coupar; D Boyle; S Chan; G Smith
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Specific immune response genes of the guinea pig. II. Relationship between the poly-L-lysine gene and the genes controlling immune responsiveness to copolymers of L-glutamic acid and L-alanine and L-glutamic acid and L-tyrosine in random-bred Hartley guinea pigs.

Authors:  H G Bluestein; I Green; B Benacerraf
Journal:  J Exp Med       Date:  1971-08-01       Impact factor: 14.307
View more
  6 in total

1.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Production of Oral Vaccines Based on Virus-Like Particles Pseudotyped with Protozoan-Surface Proteins.

Authors:  Lucía Lara Rupil; Marianela Del Carmen Serradell; Hugo Daniel Luján
Journal:  Methods Mol Biol       Date:  2022

3.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

4.  Genetic immunization using nanoparticles engineered from microemulsion precursors.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

5.  Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.

Authors:  Md Mohosin Rana
Journal:  J Biomater Sci Polym Ed       Date:  2021-04-14       Impact factor: 3.517

6.  Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes.

Authors:  Liulin Chen; Junming Zhu; Yuhong Li; Jie Lu; Li Gao; Huibi Xu; Mingwen Fan; Xiangliang Yang
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.